Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo

[1]  M. Barbacid,et al.  Afatinib restrains K-RAS–driven lung tumorigenesis , 2018, Science Translational Medicine.

[2]  P. Queirolo,et al.  Binimetinib for the treatment of NRAS-mutant melanoma , 2017, Expert review of anticancer therapy.

[3]  Lana X. Garmire,et al.  More Is Better: Recent Progress in Multi-Omics Data Integration Methods , 2017, Front. Genet..

[4]  Brooke L. Fridley,et al.  Integrative clustering of multi-level ‘omic data based on non-negative matrix factorization algorithm , 2017, PloS one.

[5]  Lodewyk F. A. Wessels,et al.  TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types , 2016, Bioinform..

[6]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[7]  R. Bernards,et al.  A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility , 2016, Cell.

[8]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[9]  J. Stenvang,et al.  A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol , 2015, BMC Cancer.

[10]  Xing-Ming Zhao,et al.  jNMFMA: a joint non-negative matrix factorization meta-analysis of transcriptomics data , 2015, Bioinform..

[11]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[12]  S. Fox,et al.  Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.

[13]  Stephen B. Montgomery,et al.  Cis and Trans Effects of Human Genomic Variants on Gene Expression , 2014, PLoS genetics.

[14]  M. Hung,et al.  Signaling cross-talk in the resistance to HER family receptor targeted therapy , 2014, Oncogene.

[15]  Clarence C Lee,et al.  Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer , 2014, Genome research.

[16]  Justin Guinney,et al.  Systematic Assessment of Analytical Methods for Drug Sensitivity Prediction from Cancer Cell Line Data , 2013, Pacific Symposium on Biocomputing.

[17]  D. Sterman,et al.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. , 2013, Clinics in chest medicine.

[18]  Z. Yakhini,et al.  Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data , 2013, PloS one.

[19]  Eric F Lock,et al.  JOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES. , 2011, The annals of applied statistics.

[20]  Jie Zheng,et al.  Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). , 2012, Oncology letters.

[21]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[22]  P. V. van Diest,et al.  Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment , 2011, Clinical Cancer Research.

[23]  M. Červinka,et al.  Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells , 2011, Apoptosis.

[24]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[25]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[26]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[27]  Rafael A Irizarry,et al.  Gene set enrichment analysis made simple , 2009, Statistical methods in medical research.

[28]  Lai Wei,et al.  Interferon-resistant Daudi Cell Line with a Stat2 Defect Is Resistant to Apoptosis Induced by Chemotherapeutic Agents* , 2009, The Journal of Biological Chemistry.

[29]  Adam B. Olshen,et al.  Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..

[30]  Seungjin Choi,et al.  Orthogonal Nonnegative Matrix Factorization: Multiplicative Updates on Stiefel Manifolds , 2008, IDEAL.

[31]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[32]  Hyunsoo Kim,et al.  Non-negative Tensor Factorization Based on Alternating Large-scale Non-negativity-constrained Least Squares , 2007, 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering.

[33]  J. Mesirov,et al.  Metagene projection for cross-platform, cross-species characterization of global transcriptional states , 2007, Proceedings of the National Academy of Sciences.

[34]  R. Redon,et al.  Relative Impact of Nucleotide and Copy Number Variation on Gene Expression Phenotypes , 2007, Science.

[35]  Paul Van Dooren,et al.  Weighted Nonnegative Matrix Factorization and Face Feature Extraction , 2007 .

[36]  Tamara G. Kolda,et al.  MATLAB Tensor Toolbox , 2006 .

[37]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[38]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. van Leeuwen,et al.  Intelligent Data Engineering and Automated Learning , 2003, Lecture Notes in Computer Science.

[41]  T. Herzog.  Update on the role of topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.

[42]  E. Van Cutsem,et al.  Optimizing the use of irinotecan in colorectal cancer. , 2001, The oncologist.

[43]  Genshiro Kitagawa,et al.  Selected papers of Hirotugu Akaike , 1998 .

[44]  R. Bro.  PARAFAC. Tutorial and applications , 1997 .

[45]  Y. Ohashi,et al.  [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[46]  Mindy Seering,et al.  Study protocol. , 1992, Occasional paper.

[47]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .